National Food Research Institute

Riken Corporation

Other

Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

Kozo Ochi

Shigeyuki Yokoyama

Mikako Shirouzu

Takanori Kigawa

Namtip Chumpolkulwong

Chie Hori

Takeshi Hosaka

Masanobu Kohsaka

Masami Ezaki

Morita Iwami

Tadaaki Komori

Hideyuki Muramatsu

Haifeng Hu

Motohiro Hino

Akihiko Fujie

Keiichi Hosokawa

It is intended to provide an extract, kit and a process for synthesizing a protein in a cell-free system. The extract is characterized by being prepared from mutantcells having a mutation in the ribosomal protein S12 gene. In a preferred embodiment, the mutation is such a mutation as conferring a resistance or dependence to streptomycin onwhereby the reading efficiency of mRNA codon on ribosomes can be improved and thus the protein productivity can be elevated.

[object Object]

This invention relates to a method for increasing the productivity of the secondary metabolite in a micro-organism, for example, the improvement of antibiotic producers by conferring drug-resistant mutations to micro-organisms.

Method for increasing productivity of secondary metabolite by conferring drug-resistant mutations

The present invention relates to mutant strains ofand their use in the detoxification of industrial and/or toxic waste products.

FR-900493 is a compound of molecular formula C.sub.20 H.sub.33 N.sub.5 O.sub.11 which may be recovered from Bacillus cultures, possesses antimicrobial activity, and may be used for the treatment and prevention of infectious diseases in humans and animals.

FR-900493 substance, a process for its production and a pharmaceutical

Growing community of inventors

Tsukuba, Japan

Kozo Ochi